BPI-472372: a potent and orally bioavailable small molecule inhibitor of CD73 for cancer immunotherapy

被引：0
|
作者：
Han, Han
Yang, Xiaofeng
Zhao, Ying
Wang, Jin
Yang, Xiang
Ju, Xuepeng
Zhao, Jiayu
Zou, Zhengyao
Chen, Haibo
Liu, Xiaoyun
Guo, Jing
Yang, Cheng
Lan, Hong
Wu, Hao
Ding, Lieming
Wang, Jiabing
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
504
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Identification of CD73 and A2AR/CD73 small molecule inhibitors for cancer immunotherapy as single agents or in combination with Immune-checkpoint therapies
    Fons, Pierre
    Bell, Andrew
    Esquerre, Michael
    Versluys, Stephanie
    Bertrand, Florie
    Schreyer, Adrian
    Hopkins-Navratilova, Iva
    Hernani, Leonardo-Silvestre
    Bergeaud, Celia
    Poussereau-Pomie, Celine
    Marchand, Ghislaine
    Robinson, Sean
    Culurgioni, Simone
    Cox, Richard
    Besnard, Jeremy
    Payne, Andrew
    Ray, Peter
    Pelissier, Emilie
    Paillasse, Michael
    Lisztwan, Joanna
    Johnstone, Craig
    Whittaker, Mark
    Hopkins, Andrew
    CANCER RESEARCH, 2019, 79 (13)
  • [22] CD73: an emerging target for cancer immunotherapy
    Wang, Long
    Fan, Jie
    Thompson, Linda
    Shin, Tahiro
    Curiel, Tyler
    Zhang, Bin
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [23] Potential of CD73 as a target for cancer immunotherapy
    Jadidi-Niaragh, Farhad
    IMMUNOTHERAPY, 2019, 11 (16) : 1353 - 1355
  • [24] CD73 as a potential opportunity for cancer immunotherapy
    Ghalamfarsa, Ghasem
    Kazemi, Mohammad Hossein
    Mohseni, Sahar Raoofi
    Masjedi, Ali
    Hojjat-Farsangi, Mohammad
    Azizi, Gholamreza
    Yousefi, Mehdi
    Jadidi-Niaragh, Farhad
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (02) : 127 - 142
  • [25] Targeting CD73 to augment cancer immunotherapy
    Roh, Meejeon
    Wainwright, Derek A.
    Wu, Jennifer D.
    Wan, Yong
    Zhang, Bin
    CURRENT OPINION IN PHARMACOLOGY, 2020, 53 : 66 - 76
  • [26] CD73: A Novel Target for Cancer Immunotherapy
    Zhang, Bin
    CANCER RESEARCH, 2010, 70 (16) : 6407 - 6411
  • [27] CD73: an emerging checkpoint for cancer immunotherapy
    Chen, Siqi
    Wainwright, Derek A.
    Wu, Jennifer D.
    Wan, Yong
    Matei, Daniela E.
    Zhang, Yi
    Zhang, Bin
    IMMUNOTHERAPY, 2019, 11 (11) : 983 - 997
  • [28] Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73
    Beatty, Joel W.
    Lindsey, Erick A.
    Thomas-Tran, Rhiannon
    Debien, Laurent
    Mandal, Debashis
    Jeffrey, Jenna L.
    Tran, Anh T.
    Fournier, Jeremy
    Jacob, Steven D.
    Yan, Xuelei
    Drew, Samuel L.
    Ginn, Elaine
    Chen, Ada
    Pham, Amber T.
    Zhao, Sharon
    Jin, Lixia
    Young, Stephen W.
    Walker, Nigel P.
    Leleti, Manmohan Reddy
    Moschuetz, Susanne
    Straeter, Norbert
    Powers, Jay P.
    Lawson, Kenneth, V
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (08) : 3935 - 3955
  • [29] Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present)
    Nocentini, Alessio
    Capasso, Clemente
    Supuran, Claudiu T.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2021, 31 (10) : 867 - 876
  • [30] Identification of a novel non-brain penetrant A2AR inhibitor and proof-of-concept of CD73 and A2AR/CD73 small-molecule inhibitors for cancer immunotherapy
    Fons, Pierre
    Bell, Andy
    Esquerre, Michael
    Versluys, Stephanie
    Bertrand, Florie
    Poussereau-Pomie, Celine
    Schreyer, Adrian
    Cox, Richard
    Besnard, Jeremy
    Paillasse, Michael
    Swindells, Mark
    Lisztwan, Joanna
    Johnstone, Craig
    Whittaker, Mark
    Hopkins, Andrew
    CANCER RESEARCH, 2018, 78 (13)
12345